Efficacy and Safety of REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)
Status:
Not yet recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, randomized, double-blind, placebo-controlled trial to evaluate efficacy,
safety, and pharmacokinetics of REC-4881 in participants with Familial Adenomatous Polyposis
(FAP).